BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20421143)

  • 41. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
    McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
    Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined ipsilateral treatment of cervical lymph nodes metastases from an unknown primary.
    Dequanter D; Lothaire P; Gastelblum P; Nguyen TH; Lalami Y; Awada A; Andry G
    B-ENT; 2008; 4(3):157-61. PubMed ID: 18949962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of IMRT techniques in the radiotherapeutic management of head and neck cancer: is tomotherapy "better" than step-and-shoot IMRT?
    Chen AM; Marsano J; Perks J; Farwell G; Luu Q; Donald PJ; Purdy JA
    Technol Cancer Res Treat; 2011 Apr; 10(2):171-7. PubMed ID: 21381795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy.
    Graff P; Lapeyre M; Desandes E; Ortholan C; Bensadoun RJ; Alfonsi M; Maingon P; Giraud P; Bourhis J; Marchesi V; Mège A; Peiffert D
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1309-17. PubMed ID: 17289292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy.
    Scrimger R; Kanji A; Parliament M; Warkentin H; Field C; Jha N; Hanson J
    Am J Clin Oncol; 2007 Jun; 30(3):271-7. PubMed ID: 17551304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Very late xerostomia, dysphagia, and neck fibrosis after head and neck radiotherapy.
    Baudelet M; Van den Steen L; Tomassen P; Bonte K; Deron P; Huvenne W; Rottey S; De Neve W; Sundahl N; Van Nuffelen G; Duprez F
    Head Neck; 2019 Oct; 41(10):3594-3603. PubMed ID: 31329343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Palliative radiation therapy for head and neck cancer: toward an optimal fractionation scheme.
    Chen AM; Vaughan A; Narayan S; Vijayakumar S
    Head Neck; 2008 Dec; 30(12):1586-91. PubMed ID: 18798313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome with neck dissection after chemoradiation for N3 head-and-neck squamous cell carcinoma.
    Igidbashian L; Fortin B; Guertin L; Soulières D; Coulombe G; Belair M; Charpentier D; Tabet JC; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):414-20. PubMed ID: 19775825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intensity-modulated radiotherapy for oropharyngeal squamous cell carcinoma.
    Mendenhall WM; Amdur RJ; Morris CG; Kirwan JM; Li JG
    Laryngoscope; 2010 Nov; 120(11):2218-22. PubMed ID: 20938964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of salivary flow and dose-volume modeling of complication incidence in patients with head-and-neck cancer receiving intensity-modulated radiotherapy.
    Marzi S; Iaccarino G; Pasciuti K; Soriani A; Benassi M; Arcangeli G; Giovinazzo G; Benassi M; Marucci L
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1252-9. PubMed ID: 19251097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Xerostomia in long-term survivors of aggressive non-Hodgkin's lymphoma of Waldeyer's ring: a potential role for parotid-sparing techniques?
    Chang DT; Amdur RJ; Pacholke H; Mendenhall NP; Morris CG; Byer GA; Olivier KR
    Am J Clin Oncol; 2009 Apr; 32(2):145-9. PubMed ID: 19307951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
    Chen AM; Li BQ; Lau DH; Farwell DG; Luu Q; Stuart K; Newman K; Purdy JA; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1026-32. PubMed ID: 20231073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma.
    Yao M; Karnell LH; Funk GF; Lu H; Dornfeld K; Buatti JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1354-60. PubMed ID: 17689885
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Diagnosis and treatment of 39 patients with cervical lymph node metastases of squamous cell carcinoma of unknown primary origin, referred to Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1979-98].
    Klop WM; Balm AJ; Keus RB; Hilgers FJ; Tan IB
    Ned Tijdschr Geneeskd; 2000 Jul; 144(28):1355-60. PubMed ID: 10923158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation.
    Portaluri M; Fucilli FI; Castagna R; Bambace S; Pili G; Tramacere F; Russo D; Francavilla MC
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1036-43. PubMed ID: 16750321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.
    Pow EH; Kwong DL; McMillan AS; Wong MC; Sham JS; Leung LH; Leung WK
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):981-91. PubMed ID: 17145528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.